Conestat alfa
Brand names: Ruconest
Conestat alfa is a recombinant human C1-esterase inhibitor used to treat acute angioedema attacks in adults and adolescents with hereditary angioedema due to C1-esterase inhibitor deficiency.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is a recombinant form of human C1-esterase inhibitor that replaces the deficient or dysfunctional protein, restoring regulation of the complement and contact (kallikrein-kinin) systems and reducing bradykinin-mediated swelling.
Prescribing in practice
- It is produced in the milk of transgenic rabbits and is contraindicated in patients with known or suspected allergy to rabbits or rabbit-derived products.
- It is administered by slow intravenous injection for the treatment of acute attacks.
- Hypersensitivity reactions can occur and may be difficult to distinguish from angioedema, so it should be given where appropriate management is available, per the SPC.
Monitoring
Monitor for resolution of the acute attack and for signs of hypersensitivity during and after administration.
Counselling the patient
- This medicine treats sudden swelling attacks of hereditary angioedema.
- Tell your clinician if you are allergic to rabbits, as it is derived from rabbit milk.
- Seek urgent help if you develop signs of an allergic reaction such as rash, wheeze or worsening swelling.
Evidence & guidelines
Conestat alfa is supported by randomised controlled trials demonstrating reduced time to relief of acute hereditary angioedema attacks.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Difficult Airway Algorithm (DAS) · DAS 2015; Royal College of Anaesthetists
- Major Haemorrhage Protocol · NICE NG24; UK MHP guidelines
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines